Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.

@article{Kennedy2014AdditionOI,
  title={Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.},
  author={Glen A. Kennedy and Antiopi Varelias and Slavica Vuckovic and Laetitia Le Texier and Kate H Gartlan and Ping Zhang and Gethin P. Thomas and Lisa K Anderson and Glen M Boyle and Nicole Cloonan and Joseph W. Leach and Elise Sturgeon and Judy Avery and Stuart D. Olver and Mary L. Lor and Ashish K. Misra and Cheryl Hutchins and Andrew J. Morton and Simon T S Durrant and Elango Subramoniapillai and Jason P. Butler and Cameron I Curley and Kelli P MacDonald and Siok-Keen Tey and Geoffrey R Hill},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 13},
  pages={
          1451-9
        }
}
BACKGROUND Interleukin 6 mediates graft-versus-host disease (GVHD) in experimental allogeneic stem-cell transplantation (allogeneic SCT) and represents an attractive therapeutic target. We aimed to assess whether the humanised anti-interleukin-6 receptor monoclonal antibody, tocilizumab, could attenuate the incidence of acute GVHD. METHODS We undertook a single-group, single-institution phase 1/2 study at the Royal Brisbane and Women's Hospital Bone Marrow Transplantation unit, QLD, Australia… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 56 CITATIONS

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 14 Citations per year over the last 3 years

Similar Papers

Loading similar papers…